>

Press Releases

YEAR
Date Description View
05/08/19

Denali Therapeutics Reports First Quarter 2019 Financial Results

03/12/19

Denali Therapeutics Reports Full Year 2018 Financial Results and Business Highlights

02/15/19

Denali Therapeutics Announces First Patient Dosed in Phase 1B Study of DNL747 for Alzheimer’s Disease

01/08/19

Denali Therapeutics Announces First Patient Dosed in Phase 1B Study of DNL747 for ALS

12/10/18

Denali Therapeutics Announces First Patient Dosed in Phase 1B Study of DNL201 for Parkinson's Disease

11/19/18

Denali Therapeutics Announces Positive Clinical Results With Its Lead RIPK1 Inhibitor Molecule and Intention to Initiate Patient Studies in Multiple Indications in Collaboration With Sanofi

11/08/18

Denali Therapeutics Reports Third Quarter 2018 Financial Results And Business Highlights And Announces The Appointment Of Jennifer Cook To Board Of Directors

10/31/18

Denali Therapeutics Announces Broad Collaboration With Sanofi To Develop RIPK1 Inhibitors For The Treatment Of Neurological And Inflammatory Diseases

10/03/18

CENTOGENE And Denali Therapeutics Announce Strategic Collaboration To Recruit LRRK2 Patients For Clinical Trials

08/09/18

Denali Therapeutics Reports Second Quarter 2018 Financial Results

Investors & Media Relations